An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

July 5, 2028

Study Completion Date

July 5, 2041

Conditions
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
Interventions
BIOLOGICAL

CAR-T(RD140 injection)

"This study is divided into two stages: dose escalation and dose extension. The dose escalation stage sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 1.0×10\^5 CART cells/kg, 3.0×10\^5 CART cells/kg and 6.0×10\^5 CART cells/kg, and subjects will receive a single infusion of RD140. Each dose group level will include 3-6 subjects.~In the dose expansion stage, 1\~2 dose groups were selected for expansion and 3\~6 subjects were included in each extended dose group, and the target dose was administered once."

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT06655519 - An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | Biotech Hunter | Biotech Hunter